The Prognostic Value of Intermedin in Patients with Breast Cancer

Abstract EN

This study aimed to evaluate the prognostic value of preoperative plasma intermedin levels in breast cancer patients.

Plasma intermedin levels of 252 breast cancer women and 100 healthy women were determined using radioimmunoassay kit.

Adverse event was defined as first local recurrence, distant metastasis, second primary cancer of another organ, or death from any cause during 5-year follow-up.

Disease-free survival was defined as the time between surgery and the date of any adverse event whichever appeared first.

Overall survival was defined from surgery to death for any cause.

The relationships between plasma intermedin levels and clinical outcomes of breast cancer patients were evaluated using multivariate analysis.

The results showed that preoperative plasma intermedin levels were substantially higher in patients than in healthy subjects using t-test.

Intermedin was identified as an independent predictor for 5-year mortality, adverse event, disease-free survival, and overall survival using multivariate analysis.

Based on receiver operating characteristic curve analysis, preoperative plasma intermedin levels had high predictive value for 5-year mortality and adverse event.

In conclusion, preoperative plasma intermedin levels are highly associated with poor patient outcomes and intermedin may be a potential prognostic biomarker for patients with breast cancer.